Announcement PDF ASX Announcement Australian Microcap Investment Conference presentation Melbourne, Australia; 21 October 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, provides a copy of the presentation delivered by CEO Cheryl Maley at the Australian Microcap Investment Conference in Melbourne today. The presentation outlined how Starpharma is delivering on its strategy, as follows: Transforming drug delivery with dendrimer technology platform Starpharma is leveraging its clinically validated DEP® dendrimer platform to develop novel assets and execute strategic partnerships, focusing on innovative drug delivery in oncology. The DEP® platform offers unique advantages in drug delivery, including enabling more precise and flexible drug design and improving efficacy and tolerability. Developing novel assets Starpharma is developingand advancing a pipelineof novel assets designed to address significant unmet needs, delivering significant patient benefit and competitive advantage. Building on our experience in chemotherapeutics, radiopharmaceuticals are an area of focus, with the global radiopharmaceuticals market projected to grow to USD $14.B (A$ 21.74B1 ) in 2034 from $7.3B (A$ 11.26B) in 2025. Starpharma’s DEP® platform is well placed to add value to the development of radiopharmaceuticals. Starpharma is progressing its HER2-targeted radiopharmaceuticals program, with plans to initiate a first-in-human trial in 2026. Securing strategic partnerships Starpharma has established high-impact partnerships with global biotech and pharmaceutical leaders. These collaborations, including the recently executed agreements with Genentech and Radiopharm Theranostics, validate the potential of the DEP® platform and could significantly expand commercial opportunities. Outlook Key catalysts over the next 12 months include progressing radiotheranostics to the clinic, expanding partnerships, converting early discovery into development programs, and increasing revenue from licensing and product sales. 1 USD:AUD exchange rate of 1.54 as at 16 October 2025 2 Visit Starpharma’s new Investor Hub to access the latest company developments, updates, and strategic insights, and submit questions. By joining our Investor Hub, you will gain access to commentary from CEO Cheryl Maley and resources designed to help you stay connected with Starpharma’s story. Scan the QR code or visit: https://investors.starpharma.com/link/epJxBP About Starpharma Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the- counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, Chief Financial and Operations Officer and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford VIC 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward- looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person asto the likelihoodofachievement or reasonablenessof future results.Nothing contained in thisdocument, norany informationmadeavailable to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. Delivering meaningful patient outcomes with advanced dendrimer technology Australian Microcap Investment Conference 21 October 2025 ASX : SPL US OTC : SPHRY Disclaimer and forward-looking statements This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 3 Starpharma is at the cutting edge of drug delivery, with validated dendrimer technology, strategic partnerships, global commercial reach, and a world- class team dedicated to delivering breakthrough health solutions. 4 Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 5 Investment highlights Transforming drug delivery for lasting impact Clinically validated DEP® platform technology More than 350 patients treated with DEP® across multiple clinical programs. Expanding commercialisation opportunities High-impact partnerships established with global biotech and pharmaceutical leaders. Broad application in high-value therapeutics DEP® dendrimers enable precise, flexible drug design across multiple therapeutics, expanding market potential. Uniquely experienced team 20 years of deep expertise in dendrimer science. Staff of ~40 people. Strong intellectual property position 23 active patent families with 119 granted patents and 40+ pending patents. Ticker ASX:SPL US OTC: SPHRY Share Price ~A$0.28 (~USD$0.19) Market Capitalisation ~A$113M Total ordinary shares on issue 418M GICS classification Pharmaceuticals, Biotechnology & Life Sciences 52-week range $0.082 - $0.345 Average daily volume ~834K Cash Balance (30 Jun 2025) A$15.4M 6 Corporate overview An innovative, biopharmaceutical company and leader in dendrimer technology Share price Allianz SE 11.8% Robmar Investments Pty Ltd 7.1% ICM Investment Management Ltd 6.4% Substantial shareholders DEP® platform 7 DEP® dendrimers A unique drug delivery technology 8 Dendrimers are highly branched (tree-like) macromolecules with a well-defined 3D structure. DEP® dendrimers are made up of concentric layers of lysine monomers (generations) that can be customised to carry payloads, drugs, and/or targeting moieties to achieve enhanced targeting and pharmacokinetics. DEP® nanoparticle Targeting moiety Drug / payload - Cytotoxic - Ultra-toxic - Radioisotope - Immunomodulator Linker / chelator PEG G2 G3 G4 G5 Dendrimer Generations Our DEP® platform technology Solving drug development challenges 9 Key Characteristics Valued by Collaborators 9 Efficacy 50% Toxicity 30% Pharmac okinetics 15% Top 3 reasons drugs FAIL in development DEP® technology advantages which can help address these challenges: • Targeted delivery: improves efficacy and reduces off- target toxicity. • Versatile targeting: compatible with many types of targeting agents. • Precise attachment: ensures predictable drug release in the body, improving efficacy and tolerability. • Customizable: can choose the right drug payload or radioactive for the desired outcome. • Flexible design: multiple ways to connect drugs and linkers for different therapies, improving stability and pharmacokinetics. • Reliable and scalable: made with precision and able to produce at scale, ensuring reproduceable efficacy, predictable pharmacokinetics and controlled toxicity. Our DEP® platform technology Harnessing multiple pathways to maximise shareholder returns DEP Platform Novel asset development Strategic partnerships 10 Multinational, private equity, biotechnology (revenue from platform license - development to commercialisation, R&D Services) Radiotheranostics, ADCs, combinations, non- oncology molecules (revenue from asset license & commercialisation) Our competitive advantage Setting the standard in drug delivery Scaffold Properties Starpharma DEP® Dendrimer Liposome PAMAM Dendrimer Drug Loading Capacity Stability and Release Chemistry Encapsulation/conjugation Biodegradable Manage PK properties Immunogenicity/safety profile Breadth of therapy areas IP coverage Novel asset development 12 Our pipeline Unlocking value through clinical-stage assets, partnerships, and marketed products 13 Internal DEP® Pipeline Product Target indication Research Pre- clinical Phase I Phase II Phase III Strategy DEP® SN38 Ovarian and colorectal License/co- develop – ovarian, colorectal DEP® cabazitaxel Prostate and gastro- oesophageal License – prostate, ovarian DEP® docetaxel Pancreatic and other cancers DEP® HER2 radiodiagnostic Diagnostic Optimise and accelerate to clinical DEP® HER2 radiotherapeutic Solid cancers Advance to clinical Early-stage projects Various Clinical results reported Clinical results reported Partnered DEP® Programs SPL7013 Products on Market Clinical results reported Pre-clinical validation of DEP® dendrimers Modifying generation (size) improves tumour accumulation via EPR, leading to improved efficacy 14 DEP® allows better targeting of drugs to cancer tissue resulting in higher drug levels Radiolabelled DEP® dendrimer-drug conjugate accumulates in tumour via EPR effect 45-70x MDA-MB-231 breast cancer model 24 h 168 h DU145 prostate cancer model DEP® cabazitaxel shows enhanced efficacy vs. standard cabazitaxel (S-CTX) 48 h Clinical validation of DEP® dendrimers DEP® SN38 shows favourable efficacy in late-stage patients Advanced Colorectal Cancer Advanced Platinum-Resistant Ovarian Cancer Data for DEP® SN38 in combination with 5-FU/LV; Full Phase II results reported in ASX Announcement dated 27 May 2024; *From published data on irinotecan in combination with 5-FU/LV, Tournigand et al., Clin Oncol, 2023, 41(19):3469-3477; # https://www.medicines.org.uk/ emc/product/6506- UK SmPC April 2022 ^From published data on ICC (investigator chemotherapy of choice) (pegylated liposomal doxorubicin, paclitaxel, or topotecan), Pujade-Lauraine E, et al., J Clin Oncol, 2014, 32(13):1302-1308; 2.8 4.2 mPFS (months) 4 14 ORR (%) 3.4 10.4 mPFS (months) 11.8 43 ORR (%) Clinical validation of DEP® dendrimers DEP® SN38 shows favourable tolerability in late-stage patients 16 Data for DEP® SN38 in combination with 5-FU/LV; Full Phase II results reported in ASX Announcement dated 27 May 2024; *From published data on irinotecan in combination with 5-FU/LV, Tournigand et al., Clin Oncol, 2023, 41(19):3469-3477; # https://www.medicines.org.uk/ emc/product/6506- UK SmPC April 2022 20% 10% 10% 47% 0.90% 0.90% 1.80% 0% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% Diarrhea ≥ Grade 3 Vomiting ≥ Grade 3 Nausea ≥ Grade 3 Cholinergic Syndrome Irinotecan DEP® SN38 Q3W N=765 Q2W, Q3W N=114 Only 1 patient with grade 3 diarrhoea from 114 patients and more than 800 doses of DEP® SN38 No cases of cholinergic symptoms with DEP® SN38 Gastrointestinal Toxicity Profile Significantly Improved with DEP® SN38 Treatment, Compared to Published Data on Irinotecan# Strategic opportunity in radiopharmaceuticals Creating differentiated assets with significant market potential 17 • Radiopharmaceuticals combine radioactive isotopes with targeting molecules to diagnose and treat cancer more precisely. • They allow whole-body imaging and targeted therapy, reducing potential damage to healthy tissue. Why radiopharmaceuticals • Global market size: USD $7.3B in 2025, projected to reach USD $14.1B in 2034 at a CAGR of 7.6%. • Therapeutic radiopharmaceuticals dominate the market, driven by demand for advanced cancer treatments. Market opportunity • Limited competition, especially for novel targets like HER2. • Competitive pricing due to few treatment options. • Strong potential for both diagnostics & therapy. Strategic drivers Starpharma’s HER2 strategy • HER2 is a key target in breast & gastric cancers, with a combined market exceeding USD $12B. • No approved HER2-targeted radio pharmaceuticals. • Potential for SPL’s DEP® platform to improve efficacy and reduce toxicity. • DEP® HER2 assets in preclinical development, with plans for a first-in-human trial in 2026. • Strong partner interest. • Recent Radiopharm Theranostics partnership validates DEP platform’s value in radiopharmaceuticals. Biodistribution Challenges with Other Approaches: Starpharma’s DEP® Technology Solution: DEP® radiotheranostics Addressing the drug delivery challenges of current approaches 18 High kidney exposure Low tumour uptake Tumour:Kidney ratio highly negative Tumour Blood Liver Spleen Kidneys Heart Lungs Colon Bone 0 5 10 15 20 25 30 %Injected dose/g Tumour:Blood ratio >40 Tumour:Blood ratio >40 Tumour:Kidney/Organ ratios highly positive due to low uptake in normal tissue LHS Image from Lizak et al, 2024, SNMMI presentation – DLL3 Radio- DARP in in tumor mouse model DEP® HER2 radiodiagnostic: faster clearance from blood and sustained elevated tumour:blood ratios compared to trastuzumab-89Zr Strategic partnerships 19 Our strategic partnerships Expanding opportunities for commercialisation 20 Exclusive License Agreement • Limited targets, multi- product • Deal value: up to ~AUD $864M plus royalties Joint Venture • Single asset focus • USD $25M investment by Medicxi • SPL holds 22.5% equity in Petalion Research and Option Agreement • Single asset focus • Deal value up to ~AUD $91M plus royalties Recent media attention following GNE deal Positioning DEP® as a next-gen oncology delivery platform beyond biologics 21 Summary & outlook 22 Our strategy & outlook Focusing on strategic execution & revenue generation Anticipated catalysts • Radiotheranostic progress to the clinic • License/collaboration for a DEP® asset to commercialise • Strategic partnerships – expansion • Converting early discovery to development program • New VivaGel® BV EU / ROW partner • Increasing revenue from licensing and product sales 23 Maximising DEP® platform value 01 Building strategic partnerships 02 Building long- term sustainability 03 Three focused strategic imperatives 24 Why Invest in Starpharma? Transforming drug delivery for lasting impact Clinically validated DEP® platform technology Expanding commercial opportunities Broad application in high-value therapeutics Uniquely experienced team Strong intellectual property position Thank you. Investor Relations Investor.Relations@Starpharma.com www.starpharma.com Corporate Office 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia ASX : SPL US OTC : SPHRY